Rich Bon Tablet 35 mg (Risedronate Sodium)

Adult dose

Adults: Administer 35 mg of risedronate sodium orally once weekly. No dose adjustment is necessary in elderly patients (over 60 years) because the bioavailability and pharmacodynamics of this drug are similar to those in younger people. No dose adjustment is necessary in patients with a creatinine clearance of 30 mL/min or higher. This drug is contraindicated in patients with severe renal impairment and a creatinine clearance of less than 30 mL/min. Food interferes with the absorption of this drug. For adequate absorption, take it at least 30 minutes before breakfast or at least 2 hours apart from food or beverages at any time of day. To help this drug reach the stomach readily and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ∼ 230 mL). Taking it with other beverages, including mineral water, may reduce absorption. Do not chew or suck this drug because of the possibility of oropharyngeal ulceration. Patients should not lie down for at least 30 minutes after taking it. If a patient forgets to take the drug on the scheduled day, take it the next morning when remembered. Resume the next dose on the originally scheduled day. Do not take 2 tablets on the same day.

Child dose

Children under 18 years of age: Safety and efficacy have not been established.

This medication may irritate the upper gastrointestinal mucosa, so patients with esophageal issues or diseases such as gastritis, duodenitis, and ulcers should take caution when using it. Especially, esophagitis, esophageal ulcers, and esophageal erosion may occur, and in severe cases, it could lead to esophageal obstruction or perforation. When taking this medication, it must be taken with a sufficient amount of water, and patients should not lie down for at least 30 minutes after taking it. Furthermore, if symptoms such as dysphagia or pain behind the sternum, heartburn occur, the patient should immediately discontinue use and consult a physician. Patients with esophageal strictures or achalasia that delay esophageal emptying, patients with hypocalcemia, pregnant or breastfeeding women, and those with severe renal impairment should not take this medication. This medication should be taken with adequate intake of calcium and vitamin D, and it is important to treat hypocalcemia and disturbances of bone and mineral metabolism prior to use. Patients undergoing dental surgery or with oral infections are at risk of jaw necrosis and should take caution, and during bisphosphonate therapy, oral hygiene management should be attended to. Although rare, atypical fractures of the femur may occur with bisphosphonate class drugs; therefore, if there is pain in the thigh or groin, the physician should be informed. This medication contains lactose; therefore, patients with lactose intolerance should not take it. When taking this medication with other medications, it should be avoided with antacids or supplements containing calcium, magnesium, or iron. Pregnant or potentially pregnant women and breastfeeding mothers should avoid taking this medication. Safety and efficacy in children have not been established, and elderly patients can use it without special precautions. In the case of overdose, blood calcium and phosphate levels may decrease; thus, if symptoms of hypocalcemia appear, treatment should be initiated immediately. This medication should be stored out of reach of children and should not be transferred to other containers.

• Esophagitis
• esophageal ulcer
• esophageal erosion
• esophageal obstruction
• esophageal perforation
• hemorrhage
• infection
• back pain
• accidental injury
• pain

This medication should be stored in a tightly sealed container to prevent air and moisture contamination, and it is recommended to store it at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication and ensure its safe use.

Appearance

Pale orange rectangular film-coated tablet

Package unit

4 tablets (4 tablets/PTP X 1)